Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 5/20 | 0.45 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61876 | 0.86 | MGAM (0.64) | MGAMESR2PDGFRBPDGFRAMEN1 | |
| SCHEMBL69368 | 0.85 | MGAM (0.68) | MGAMPDGFRBPDGFRAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2749769 | 0.84 | MGAM (0.62) | MGAMESR2PDGFRBPDGFRAMEN1 | |
| SCHEMBL9939727 | 0.82 | ESR2 (0.73) | MGAMESR2PDGFRBPDGFRAMEN1 | |
| SCHEMBL4158038 | 0.81 | MGAM (0.62) | MGAMPDGFRBPDGFRAHPGDSPSMD14 | |
| SCHEMBL21063895 | 0.81 | MGAM (0.62) | MGAMESR2PDGFRBPDGFRAMEN1 | |
| SCHEMBL29373133 | 0.81 | MGAM (0.62) | MGAMPDGFRBPDGFRAMEN1KMT2A | |
| SCHEMBL6769263 | 0.81 | MGAM (0.62) | MGAMMEN1KMT2AALDH1A1HPGDS | |
| SCHEMBL10473057 | 0.81 | MGAM (0.62) | MGAMMEN1KMT2AALDH1A1HPGDS | |
| SCHEMBL1352602 | 0.81 | MGAM (0.62) | MGAMALDH1A1HPGDSPSMD14P4HA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114656372-B | P-phenylenediamine bridging compound and application thereof in preparation of medicines for treating sugar metabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-114573476-B | Linear head-tail diamine bridging compound and application thereof in preparation of medicines for treating sugar metabolic disorder diseases | 广州药本君安医药科技股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-114656371-B | 1, 4-cyclohexanediamine bridged compounds and their use in the treatment of disorders of glucose metabolism | 广州药本君安医药科技股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-114656372-A | P-phenylenediamine bridged compound and application thereof in preparation of medicines for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114656371-A | 1, 4-cyclohexanediamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114573476-A | Linear head-tail diamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-112500314-B | Compound, preparation method thereof and application thereof in preparing medicament for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3390384-B1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2021-09-15 | — | — | EP | disclosed |
| EP-3390384-B1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2021-09-15 | — | — | EP | disclosed |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011146591-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-7977354-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | INSA ROUEN (FR) | 2011-07-12 | — | — | US | disclosed |
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2009-03-05 | — | — | US | disclosed |
| EP-1868998-A2 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | Insa Rouen (FR) | 2007-12-26 | — | — | EP | disclosed |
| EP-1731507-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | Institut National des Sciences Appliquees de Rouen (INSA) (FR) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006103120-A2 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2006-10-05 | — | — | WO | disclosed |
| CN-1349990-A | Heterocyclic compound, its preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-05-22 | — | — | CN | disclosed |
| CN-1077107-C | Heterocyclic compounds, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-01-02 | — | — | CN | disclosed |
| CN-1223653-A | Heterocyclic compounds, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | NLN, SNCA, APP | MGAM 3096/4885ESR2 1693/4885PDGFRB 4730/4885 |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | MGAM 4458/4885ESR2 2010/4885PDGFRB 128/4885 |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | HPGDS, PTGS1, PTGIS | MGAM 3150/4885ESR2 2517/4885PDGFRB 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.